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ANTIMICROBIAL DRUGS
Novel Antimicrobial Class 
Bacterial adaptation makes antibacterial drug resistance
inevitable. As old medicines lose their effectiveness, scien-
tists must find new drugs that can safely treat a broad spec-
trum of bacterial infections.  For more than 30 years, the
problem has been addressed by improving old classes of
drugs. However, with this approach, we stay just ahead of
the evolving bacteria; and the strategy becomes more dif-
ficult with each iteration. No truly new classes of orally
active, broad-spectrum antimicrobial agents have been dis-
covered since quinolones. Aclass of broad-spectrum novel
ribosome inhibitors (NRI) has been found that shut down
bacterial protein synthesis. Although many existing
antimicrobial agents act against the ribosome, the NRIs
exploit a new mechanism of action. Because bacterial pop-
ulations are not familiar with NRIs, no preexisting resist-
ance mechanisms exist in bacteria, and NRIs have consis-
tent antimicrobial activity even against multiple drug-
resistant strains.
The team conducted a comprehensive series of biolog-
ic and biochemical experiments to discover and character-
ize the new class, as recently reported in the journal
Antimicrobial Agents and Chemotherapy. NRIs inhibit
ribosomes of both gram-positive and -negative pathogenic
bacteria but will not disturb eukaryotic protein synthesis.
Furthermore, the new compounds inhibit bacterial growth
without toxicity to human cells, consistent with developing
a new drug that kills bacteria without disturbing the human
host. As further evidence of the ribosomal mechanism, the
group showed that bacteria treated with NRI compounds
respond by trying to overproduce ribosomal proteins. As
with other ribosome inhibitors, the bacteria seem to realize
that their ribosomes are failing, and they desperately try to
make more to survive. In the laboratory, bacteria could be
made less susceptible to NRIs by certain mutations in their
ribosomes. Although, fortunately, these mutations would
be difficult to generate outside the laboratory, they were
useful in supporting the novel mechanism of action, since
these genetic alterations did not affect the action of other
ribosomal drugs. The recent data hold hope for new
antimicrobial agents that can combat the rising tide of
microbial resistance.
Dandliker PJ, Pratt SD, Nilius AM, Black-Schaefer C, Ruan X,
Towne DL, et al. Novel antibacterial class. Antimicrob Agents
Chemother. 2003;47:3831–9. 
INFLUENZA
Influenza Viruses with Genes 
from the 1918 Pandemic Virus
Eighty-six years ago, an influenza A H1N1 virus swept
the globe and killed an estimated 20–40 million people.
The exceptionally high death rate, especially among young
adults, was not observed during later influenza pandemics
of 1957 and 1968. Genetic sequence analysis of the 1918
“Spanish” influenza virus genes has not shown any fea-
tures that could account for its high virulence. Therefore,
we generated recombinant influenza (A/WSN/33) viruses
possessing 1918 influenza gene segments to provide
insights into the pathogenicity and to identify possible vac-
cine strategies against potentially reemergent 1918 or
1918-like viruses. Analysis of the recombinant influenza
viruses points to a critical role of the 1918 hemagglutinin
(HA) and neuraminidase (NA) influenza genes in viru-
lence in the mouse model.  The antigenic analysis demon-
strated that the 1918 recombinant viruses most closely
resembled a common influenza laboratory strain,
A/Swine/Iowa/30. In fact, human survivors of the 1918
influenza pandemic had antibodies that neutralized both
the 1918 HA/NA (1918 HA/NA:WSN) recombinant virus
and the A/Swine/Iowa/30 virus.  In studies, the protection
provided by A/Swine/Iowa/30 vaccine was similar to that
observed in mice that received inactivated 1918
HA/NA:WSN virus vaccine. Mice that were immune to
A/Swine/Iowa/30 were protected against death and major
weight loss and had undetectable virus in respiratory tis-
sues on day 5 after virus challenge with the lethal 1918
HA/NA:WSN virus. The protection induced by
A/Swine/Iowa/30 virus vaccine correlated with detectable
virus–neutralizing antibodies measured in the mouse.
These vaccine strategies, with data demonstrating that
existing anti-influenza drugs would be effective against
1918 virus genes, provide the basis for prophylactic meas-
ures against the reemergence of new 1918-like viruses.
Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne
DE, Basler CF. Pathogenicity and immunogenicity of influenza virus-
es with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S
A. 2004;101:3166–71. Epub 2004 Feb 12. 
Influenza Virus Tropisms
Human and avian influenza viruses target different cell
types in human airway epithelium. Recent outbreaks of
avian influenza infections in humans highlighted the threat
of pathogenic influenza viruses emerging from a huge nat-
ural reservoir in birds. To initiate the infection, avian
influenza viruses bind to cell-surface receptors containing
terminal sialyl-galactosyl residues linked by 2-3-linkage,
whereas human viruses, including the earliest available
The opinions expressed by authors contributing to this journal do
not necessarily reflect the opinions of the Centers for Disease
Control and Prevention or the institutions with which the authors
are affiliated.pandemic isolates, bind to receptors that contain terminal
2-6–linked sialyl-galactosyl residues. It is believed that a
nonoptimal receptor specificity of avian viruses limits
their replication in human respiratory tract and pandemic
spread, but the mechanism of this restriction is not clear.
Ciliated epithelium of conducting airways consists of sev-
eral distinct cell types with different functions, but the
roles of specific cell types in virus replication have not
been defined. To investigate cellular tropism of influenza
viruses, the authors employed cultures of differentiated
human airway epithelial cells which closely mimic airway
epithelium in vivo. The authors found that human viruses
preferentially infected nonciliated cells, whereas avian
viruses mainly infected ciliated cells; this pattern correlat-
ed with cell type–specific distribution of sialic acid recep-
tors recognized by the viruses. This study suggests that two
widely held concepts concerning influenza viruses (uni-
form susceptibility of airway epithelial cells to human
viruses and a lack of receptors for avian viruses) are incor-
rect. These data provide insight on the emergence of pan-
demic viruses and open avenues for cellular studies on
influenza virus replication and pathogenicity in humans.
Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD.
Human and avian influenza viruses target different cell types in cul-
tures of human airway epithelium. Proc Natl Acad Sci U S A.
2004;101:4620–4. Epub 2004 Mar 15. 
INFECTIOUS DISEASE 
ARCHAEOLOGY
Chagas Disease
In this study, investigators reconstructed the behavior
of Chagas disease (American trypanosomiasis) in the
Atacama Desert over the past 9,000 years. The researchers
analyzed ancient DNA to identify kinetoplast DNA of
Trypanosoma cruzi, the disease’s infectious agent trans-
mitted by the insect vector, a triatomid bug. Specimens
analyzed were from muscle and visceral tissues in excavat-
ed, naturally mummified human bodies buried in that
hyperarid desert during the past 9 millennia.
Results indicated that 41% of these bodies were infect-
ed by T. cruzi at the time of death. Among the 11 represent-
ed populations, no statistically significant differences in
prevalence rates could be demonstrated when studied by
the time period, sex, or age, except for lower rates (28%)
for infants. Such prevalence rates are similar to those of
modern T. cruzi–endemic areas. These results demonstrat-
ed the well-established presence of Chagas disease in this
region among wild forest animals when the first humans
(the Chinchorro) arrived. By settling this region, the new
arrivals initially and inadvertently exposed themselves to
the triatomid bug transmitting this disease, and joined the
wild animals as part of the disease’s reservoir. At some
undetermined time during this 9,000-year interval, a few of
the vector species became adapted to the thatched roof and
other features of the region’s human dwellings and initiat-
ed the independent domestic cycle involving only humans
and their domesticated animals. The study also suggests
that, given available specimens, the history of other infec-
tious diseases can be similarly reconstructed.
Aufderheide AC, Salo W, Madden M, Streitz J, Buikstra J, Guhl F, et
al. A9,000-year record of Chagas’disease. Proc Natl Acad Sci U S A.
2004;101:2034–9. Epub 2004 Feb 06. 
MICROBIAL VIRULENCE
Polysaccharide Intercellular Adhesin
Coagulase-negative staphylococci, with Staphylo-
coccus  epidermidis as the most frequently isolated
species, have become the leading cause of hospital-
acquired infections and infections of indwelling medical
devices. In the course of these infections, biofilm forma-
tion and the ability to escape from host immune defense
are regarded as the main virulence determinants. However,
the factors protecting S. epidermidis from the immune sys-
tem have remained elusive. Scientists have discovered the
first specific molecule involved in immune evasion in S.
epidermidis. The exopolysaccharide polysaccharide inter-
cellular adhesin (PIA) was located at the cell surface of S.
epidermidis; it protected organisms against phagocytosis
by neutrophils, antibacterial peptides from human skin,
and neutrophil granula. PIA was also indispensable for the
formation of cellular aggregates. The positively charged
PIA likely functions both as a mechanical barrier against
peptides and phagocytes, and by electrostatic repulsion of
the predominantly cationic antibacterial peptides. Thus, by
inhibiting major mechanisms of the human innate immune
defense, PIAmay significantly contribute to the success of
S. epidermidis in chronic infections. Interestingly, the
genetic basis for PIAproduction is present in an increasing
number of microorganisms, including such pathogenic
species as Yersinia pestis, the causative agent of plague.
Targeting PIA as a crucial component of both cell-cell
aggregation and immune evasion processes might there-
fore constitute a promising way to interfere with the viru-
lence of a series of important bacterial pathogens.
Vuong C, Voyich JM, Fischer ER, Braughton KR, Whitney AR,
DeLeo FR, et al. Polysaccharide intercellular adhesion (PIA) protects
Staphylococcus epidermidis against major components of the human
innate immune system. Cell Microbiol. 2004;6:269–75. 
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